Breaking Down SG&A Expenses: Pfizer Inc. vs Evotec SE

A Comparative Analysis of SG&A Expenses: Pfizer Inc. vs. Evotec SE

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Pfizer Inc. and Evotec SE, from 2014 to 2023.

Key Insights

Pfizer Inc., a global pharmaceutical giant, consistently reported SG&A expenses averaging around $14 billion annually. Despite fluctuations, Pfizer's expenses remained relatively stable, with a notable dip in 2020, likely due to pandemic-related operational shifts.

In contrast, Evotec SE, a leading drug discovery and development company, exhibited a remarkable growth trajectory. Starting with expenses of approximately $18 million in 2014, Evotec's SG&A expenses surged by over 800% to reach $170 million by 2023. This growth reflects Evotec's expanding operations and strategic investments.

Conclusion

This comparative analysis highlights the contrasting financial strategies of Pfizer and Evotec, offering valuable insights into their operational priorities and market positioning.